Start-ups
 » R&D » Start-ups

Currently six SME's have their own teams working in IBET's premises:

ALFAMA is a biotech start-up company dedicated to the development of new drugs against inflammation-related diseases such as rheumatoid arthritis, gastric ulcer and pulmonary hypertension, among others. The main technology created and developed by Alfama is based on Carbon Monoxide Releasing Molecules (CORMs), which are believed to have the potential to become the most powerful solution for the abovementioned diseases, thus holding the promise to become marketed products with a very high social and economic impact. Alfama gathers an international team of experts with outstanding track-records as pharmaceutical executives, academic scientists and venture-backed entrepreneurs. The company is headquartered in the United States and Portugal, and its laboratory work is performed around Lisbon and Boston. In 2005 Alfama raised the largest round of Venture Capital for any Portuguese biotech company and was elected the best startup in Europe by the European Commission’s Venture Contest, beating 300 contestants from 22 countries.

More information in http://www.alfama.com.pt/

ECBio is a biotechnology company active in developing highly effective processes to decrease the time from discovery to the commercialization of new therapeutic solutions. ECBio focuses on the development of animal cell culture processes, namely, cell line construction and selection, cell culture optimization, cell cryopreservation, toxicological testing and recombinant protein production. With the advent of cell therapies now opening new research avenues and widening the application range of human stem cells, ECBio is also investing in stem cell and human cell technologies for clinical applications.

More information in http://www.ecbio.com/

GenIBET is a CMO offering comprehensive cGMP services for proteins, virus and plasmid DNA, from pre-clinical to Phase II clinical trials, including:

  • •Upstream and Downstream Process Development;
  • •Optimization and Scale-Up for various expression systems;
  • –Mammalian, microbial, virus;
  • •GMP Cell Banking;
  • •GMP Contract Manufacturing;
  • •Viral Clearance;
  • •Assay Development;
  • •Quality Control and Quality Assurance;
  • •Regulatory Compliance.

 More information in http://www.genibet.eu

RAIZ started its activity in January 1996. It is a private non-profit research institute committed to support the competitiveness of the Portuguese Pulp and Paper Industry, through research, technology transfer and training. RAIZ activities are financed by partner companies in a perspective of transforming knowledge in technology, in order to increase forest productivity, improve pulp quality (reducing production costs and improving paperquality) and implementing sustainable forest management practices. RAIZ budget for 2007 is of three million and two hundred Euro. It has 41 permanent workers of which 20 are researchers.

More information in http://www.raiz-iifp.pt

STAB VIDA is a company owned in its majority by STAB VIDA SGPS, Grupo Stab’s sub-holding company dedicated to the biotech sector. STAB VIDA emerged in the middle of 2000, following the great enlargement of business activities inside Grupo Stab. It is also on of the pioneer biotech start-ups in Portugal, created with the intent of developing products and providing services to the Portuguese clinical and research areas. STAB VIDA is a genomics and proteomics company (DNA expression studies using microarrays and small-scale protein production) that also provides services in the area of identification of harmful microorganisms (spoilage yeast in food and beverage and Legionella pneumophila in public buildings). Additionally STAB VIDA detains capacity for DNA sequencing and genotyping. STAB VIDA has its own property technology in spoilage yeast identification.

More information in http://www.stabvida.com

 

Theraproteins

TheraProteins acts as a partner for the biotechnological industry in the analysis of recombinant glycoprotein therapeutics. Theraproteins produces and commercialises pure N-linked oligosaccharides structures (from recombinant cell lines : CHO. HEK, BHK cells ) to be used as reference standards in the development of recombinant glycoproteins (in applications e.g. lot-to-lot consistency and stability studies; as standards in chromatography, mass spectrometry and NMR). Theraproteins can also provide glycopeptides (5-20 aa) with defined glycosylation (antennarity, sialylation).

For more information, please contact:
Helder J. S. Cruz, PhD, MBA
General Manager

helder.cruz@thera-proteins.com